Halozyme Therapeutics Inc (HALO)

[rod5247]

Expert Rev Gastroenterol Hepatol. 2015 Nov 27:1-16. [Epub ahead of print]

The role of hypoxia in pancreatic cancer: a potential therapeutic target?

Erkan M1, Kurtoglu M2, Kleeff J3,4.



Author information

1a Department of Surgery , Koç University School of Medicine , Istanbul , Turkey.
2b Department of Oncology , Koç University School of Medicine , Istanbul , Turkey.
3c Department of Surgery , The Royal Liverpool and Broadgreen University Hospitals , Liverpool , UK.
4d Department of General-, Visceral- and Pediatric Surgery , University Hospital Düsseldorf, Heinrich Heine University Düsseldorf , Düsseldorf , Germany.

Abstract

One of the key factors that correlates with poor survival of patients with pancreatic cancer is the extent of hypoxic areas within the tumor tissue. The adaptation of pancreatic cancer cells to limited oxygen delivery promotes the induction of an invasive and treatment-resistant phenotype, triggering metastases at an early stage of tumor development, which resist in most cases adjuvant therapies following tumor resection. In this article, the authors summarize the evidence demonstrating the significance of hypoxia in pancreatic cancer pathogenesis and discuss the possible hypoxia-induced mechanisms underlying its aggressive nature. We then conclude with promising strategies that target hypoxia-adapted pancreatic cancer cells.


KEYWORDS:

PEGPH20; Pancreatic cancer; TH-302; cancer stem cell; desmoplasia; epithelial-to-mesenchymal transition; hypoxia; metabolism


PMID: 26560854 [PubMed - as supplied by publisher]


http://www.ncbi.nlm.nih.gov/pubmed/26560854